Safety and virologic impact of haploidentical NK cells plus IL-2 or N-803 in HIV infection May 10, 2024 | HIV
Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach May 10, 2024 | Uncategorized
ANKTIVA Synergizes with T Cell Activity of BCG in Both the Naïve and Unresponsive Setting by Activating NK Cells, Interferon Gamma, and Driving Memory CD8+ Killer T Cells May 2, 2024 | Bladder Cancer
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation Feb 29, 2024 | Uncategorized
Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Feb 9, 2024 | Uncategorized
